Marshall Wace’s Y-mAbs Therapeutics YMAB Stock Holding History

Marshall Wace’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,181	Closed	-$181K	–	3492
2025 Q2	$181K	Buy	+40,181	New	+$181K	﹤0.01%	2474
2025 Q1	–	Sell	-49,225	Closed	-$385K	–	3160
2024 Q4	$385K	Buy	49,225 +33,716	+217%	+$411K	﹤0.01%	2142
2024 Q3	$204K	Buy	+15,509	New	+$197K	﹤0.01%	2291
2024 Q1	–	Sell	-114,786	Closed	-$783K	–	2862
2023 Q4	$783K	Buy	114,786 +15,855	+16%	+$91.7K	﹤0.01%	1562
2023 Q3	$539K	Sell	98,931 -28,737	-23%	-$167K	﹤0.01%	1697
2023 Q2	$867K	Buy	+127,668	New	+$957K	﹤0.01%	1779
2022 Q4	–	Sell	-20,470	Closed	-$295K	–	3489
2022 Q3	$295K	Buy	+20,470	New	+$339K	﹤0.01%	2958
2021 Q3	–	Sell	-12,310	Closed	-$415K	–	3494
2021 Q2	$415K	Buy	+12,310	New	+$395K	﹤0.01%	2212
2019 Q4	–	Sell	-1,100	Closed	-$29K	–	2126
2019 Q3	$29K	Buy	+1,100	New	+$28.1K	﹤0.01%	1574

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's YMAB Position: Q3 2025 in Review

Marshall Wace sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 40,181 shares — an estimated $181K sold.

Marshall Wace first reported a position in YMAB in Q3 2019 and held it in 9 quarters. The position peaked at $867K in Q2 2023. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Marshall Wace reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Marshall Wace sold 40,181 Y-mAbs Therapeutics shares in Q3 2025, an estimated $181K.
Marshall Wace first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 9 quarters.
Marshall Wace's Y-mAbs Therapeutics position peaked at $867K in Q2 2023.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.